Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/6353
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bukusi, Elizabeth | - |
dc.contributor.author | Mmbaga, T. Blandina | - |
dc.contributor.author | Chepkemoi, Winnie | - |
dc.contributor.author | Chesumbai, Gladys | - |
dc.contributor.author | Ayuo, Paul | - |
dc.contributor.author | Akoko, Larry | - |
dc.date.accessioned | 2022-05-18T08:17:51Z | - |
dc.date.available | 2022-05-18T08:17:51Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.uri | https://doi.org/10.1186/s12885-021-09124-5 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/6353 | - |
dc.description.abstract | Background: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diag- nosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radia- tion therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined. Methods: This prospective, observational, multi-center, open cohort study aims to describe the therapeutic land- scape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Ten- wek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach.Discussion: This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.subject | Esophageal cancer | en_US |
dc.subject | Survival | en_US |
dc.subject | Esophageal squamous cell carcinoma, | en_US |
dc.title | Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.